- Trial phase
- Preclinical / Early-stage development (DPI formulation); Oral formulation is Phase 3 completed / NDA under FDA review
- Time to market
- The DPI formulation is early-stage with no clinical trials announced, so potential approval is likely several years away (5+ years under typical timelines). The oral formulation has a PDUFA decision date of June 24, 2027.
- Why 3/10
- No hard dated catalyst exists for the ralinepag DPI program specifically within the next ~12 months. The oral formulation's PDUFA (June 24, 2027) is a United Therapeutics event, not a MannKind catalyst. The DPI program is early-stage with no announced clinical trial start or data readout. For MannKind, ralinepag DPI is a small, distant pipeline program among multiple revenue drivers (Afrezza, Tyvaso DPI royalties, Furoscix, nintedanib DPI).
The next catalyst for ralinepag overall is the FDA PDUFA decision on the oral formulation on June 24, 2027, but that is a United Therapeutics (UTHR) event. For MannKind's ralinepag DPI program specifically, there is no announced clinical trial start or data readout date. Watch for MannKind to initiate clinical trials for MNKD-1501, which would signal progression of the DPI program. MannKind's nearer-term catalysts include its Q4 2026 profitability target and the SCP-111 FDA decision by December 31, 2026.
Price Chart
Executive Summary
Ralinepag DPI (dry powder inhalation, code MNKD-1501) is an early-stage reformulation of United Therapeutics' oral prostacyclin receptor agonist ralinepag, being developed by MannKind using its proprietary DPI technology. The oral version of ralinepag completed a successful Phase 3 ADVANCE OUTCOMES trial (55% reduction in clinical worsening risk) and has an FDA NDA accepted with a PDUFA date of June 24, 2027, but that decision belongs to United Therapeutics, not MannKind. The DPI formulation was announced in May 2026 with a $5 million payment from UTHR to MNKD, targeting pulmonary hypertension and fibrotic lung diseases. The DPI program is early-stage with no announced clinical trial initiation or data readout, making it a small, distant pipeline contributor for MannKind relative to its commercial products (Afrezza, Tyvaso DPI royalties, Furoscix).
How It Works
Ralinepag is a prostacyclin receptor agonist, meaning it mimics a natural substance (prostacyclin) that dilates blood vessels in the lungs and reduces blood pressure in the pulmonary arteries. The DPI (dry powder inhaler) formulation delivers the drug directly to the lungs via inhalation, which could improve lung delivery and reduce side effects compared to the oral version. MannKind applies its proprietary Technosphere DPI technology to create the inhaled formulation.
Trial Status
The oral formulation of ralinepag completed the pivotal Phase 3 ADVANCE OUTCOMES trial, which met its primary endpoint with a 55% reduction in risk of clinical worsening in PAH patients (published in The Lancet). The FDA accepted the NDA for oral ralinepag in August 2026 with a PDUFA date of June 24, 2027. The DPI formulation (MNKD-1501) was announced in May 2026 as being in development by MannKind in collaboration with United Therapeutics. No clinical trials for the DPI formulation have been announced or initiated as of November 2026.
The Two-Sided Case
Upcoming Catalysts
- FDA PDUFA decision on oral ralinepag: June 24, 2027 (UTHR event, not MNKD)
- Initiation of clinical trials for ralinepag DPI (MNKD-1501) - no date announced
- MannKind Q4 2026 profitability target
- SCP-111 FDA approval decision by December 31, 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MannKind PRESS-RELEASE MNKD ·Originating report